MA59824B1 - Procédés de préparation d'un inhibiteur de jak1 - Google Patents

Procédés de préparation d'un inhibiteur de jak1

Info

Publication number
MA59824B1
MA59824B1 MA59824A MA59824A MA59824B1 MA 59824 B1 MA59824 B1 MA 59824B1 MA 59824 A MA59824 A MA 59824A MA 59824 A MA59824 A MA 59824A MA 59824 B1 MA59824 B1 MA 59824B1
Authority
MA
Morocco
Prior art keywords
preparing
methods
jak1 inhibitor
jak1
inhibitor
Prior art date
Application number
MA59824A
Other languages
English (en)
Inventor
Zhongjiang JIA
Jiacheng Zhou
Yingrui DAI
Yongchun Pan
Jianji Wang
James M. Parks
Anthony J. TOMAINE
Aibin ZHANG
Original Assignee
Incyte Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corporation filed Critical Incyte Corporation
Publication of MA59824B1 publication Critical patent/MA59824B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/26—Catalysts comprising hydrides, coordination complexes or organic compounds containing in addition, inorganic metal compounds not provided for in groups B01J31/02 - B01J31/24
    • B01J31/28—Catalysts comprising hydrides, coordination complexes or organic compounds containing in addition, inorganic metal compounds not provided for in groups B01J31/02 - B01J31/24 of the platinum group metals, iron group metals or copper

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La présente invention concerne des procédés de préparation de 4-[3-(cyanométhyl)-3-(3',5'-diméthyl-1H,1'H-4,4'-bipyrazol-1-yl)azétidin-1-yl]-2,5-difluoro-N-[(1S)-2,2,2-trifluoro-1-méthyléthyl]benzamide et un sel d'acide phosphorique correspondant, qui est utile en tant qu'inhibiteur sélectif (Januskinase 1) de JAK1, ainsi que des formes salines et des intermédiaires associés.
MA59824A 2020-06-02 2021-06-02 Procédés de préparation d'un inhibiteur de jak1 MA59824B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063033618P 2020-06-02 2020-06-02
PCT/US2021/035400 WO2021247668A1 (fr) 2020-06-02 2021-06-02 Procédés de préparation d'un inhibiteur de jak1
EP21734728.5A EP4157831B1 (fr) 2020-06-02 2021-06-02 Procédés de préparation d'un inhibiteur de jak1

Publications (1)

Publication Number Publication Date
MA59824B1 true MA59824B1 (fr) 2024-11-29

Family

ID=76601838

Family Applications (1)

Application Number Title Priority Date Filing Date
MA59824A MA59824B1 (fr) 2020-06-02 2021-06-02 Procédés de préparation d'un inhibiteur de jak1

Country Status (32)

Country Link
US (1) US11685731B2 (fr)
EP (1) EP4157831B1 (fr)
JP (1) JP7802696B2 (fr)
KR (1) KR20230027086A (fr)
CN (1) CN115836065B (fr)
AR (1) AR122505A1 (fr)
AU (1) AU2021283271A1 (fr)
BR (1) BR112022024632A2 (fr)
CA (1) CA3184275A1 (fr)
CL (3) CL2022003363A1 (fr)
CO (1) CO2022017344A2 (fr)
CR (1) CR20220612A (fr)
DK (1) DK4157831T3 (fr)
EC (1) ECSP22091930A (fr)
ES (1) ES2998487T3 (fr)
FI (1) FI4157831T3 (fr)
HR (1) HRP20241560T1 (fr)
HU (1) HUE069125T2 (fr)
IL (1) IL298118B2 (fr)
LT (1) LT4157831T (fr)
MA (1) MA59824B1 (fr)
MD (1) MD4157831T2 (fr)
MX (1) MX2022015221A (fr)
PE (1) PE20231102A1 (fr)
PH (1) PH12022553277A1 (fr)
PL (1) PL4157831T3 (fr)
PT (1) PT4157831T (fr)
RS (1) RS66432B1 (fr)
SI (1) SI4157831T1 (fr)
SM (1) SMT202400509T1 (fr)
TW (1) TWI897972B (fr)
WO (1) WO2021247668A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE033587T2 (hu) 2013-05-17 2017-12-28 Incyte Corp Bipirazol-származékok mint JAK inhibitorok
KR102925957B1 (ko) 2018-02-16 2026-02-11 인사이트 코포레이션 사이토카인-관련 장애의 치료를 위한 jak1 경로 억제제
US11992490B2 (en) 2019-10-16 2024-05-28 Incyte Corporation Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP)
CA3204374A1 (fr) 2020-12-08 2022-06-16 Incyte Corporation Inhibiteurs de la voie jak1 destines au traitement du vitiligo
UA129643C2 (uk) 2021-05-03 2025-06-18 Інсайт Корпорейшн Інгібітори шляху jak1 для лікування вузлуватого свербця

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
PT1107964E (pt) 1998-08-11 2010-06-11 Novartis Ag Derivados de isoquinolina com actividade inibidora da angiogénese
US6133031A (en) 1999-08-19 2000-10-17 Isis Pharmaceuticals Inc. Antisense inhibition of focal adhesion kinase expression
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
KR100786927B1 (ko) 2000-06-28 2007-12-17 스미스클라인비이참피이엘시이 습식 분쇄방법
BR0212760A (pt) 2001-09-19 2004-12-07 Aventis Pharma Sa Compostos quìmicos
DE60213842T2 (de) 2001-10-30 2007-09-06 Novartis Ag Staurosporin-derivate als hemmer der flt3-rezeptor-tyrosinkinase-wirkung
PE20040522A1 (es) 2002-05-29 2004-09-28 Novartis Ag Derivados de diarilurea dependientes de la cinasa de proteina
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
TWI335913B (en) 2002-11-15 2011-01-11 Vertex Pharma Diaminotriazoles useful as inhibitors of protein kinases
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
AR045944A1 (es) 2003-09-24 2005-11-16 Novartis Ag Derivados de isoquinolina 1.4-disustituidas
AU2005309019A1 (en) 2004-11-24 2006-06-01 Novartis Ag Combinations of JAK inhibitors and at least one of Bcr-Abl, Flt-3, FAK or RAF kinase inhibitors
SG10202003901UA (en) 2005-12-13 2020-05-28 Incyte Holdings Corp Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
CL2008001709A1 (es) 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
KR20150036210A (ko) 2007-06-13 2015-04-07 인사이트 코포레이션 야누스 키나제 억제제（Ｒ）―３―（４―（７Ｈ―피롤로［２，３－ｄ］피리미딘―4―일）―1Ｈ―피라졸―1―일）―３―사이클로펜틸프로판니트릴의 염
UA104849C2 (uk) 2007-11-16 2014-03-25 Інсайт Корпорейшн 4-піразоліл-n-арилпіримідин-2-аміни і 4-піразоліл-n-гетероарилпіримідин-2-аміни як інгібітори кіназ janus
HUE029767T2 (en) 2008-03-11 2017-04-28 Incyte Holdings Corp JAK inhibitor azetidine and cyclobutane derivatives
CL2009001884A1 (es) 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
TWI720517B (zh) 2009-01-15 2021-03-01 美商英塞特公司 製造ｊａｋ抑制劑之方法及相關中間化合物
AR076794A1 (es) 2009-05-22 2011-07-06 Incyte Corp Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo [2,3-d]pirimidinas y pirrol-3-il-pirrolo [2,3-d ]pirimidinas como inhibidores de la quinasa janus y composiciones farmaceuticas que los contienen
SI2432472T1 (sl) 2009-05-22 2019-11-29 Incyte Holdings Corp 3-(4-(7H-pirolo(2,3-d)pirimidin-4-il)-1H-pirazol-1-il)oktan- ali heptan-nitril kot inhibitorji JAK
TW201113285A (en) 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
EA021478B1 (ru) 2009-10-09 2015-06-30 Инсайт Корпорейшн ГИДРОКСИЛЬНЫЕ, КЕТО И ГЛЮКУРОНИДНЫЕ ПРОИЗВОДНЫЕ 3-(4-(7Н-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)-1Н-ПИРАЗОЛ-1-ИЛ)-3-ЦИКЛОПЕНТИЛПРОПАННИТРИЛА
JP5858434B2 (ja) 2010-02-18 2016-02-10 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｊａｎｕｓキナーゼ阻害薬としてのシクロブタンおよびメチルシクロブタン誘導体
EP3354652B1 (fr) 2010-03-10 2020-05-06 Incyte Holdings Corporation Dérivés de pipéridine-4-yl azétidine utilisés en tant qu'inhibiteurs de jak1
KR20130094710A (ko) 2010-04-14 2013-08-26 어레이 바이오파마 인크. Ｊａｋ 키나아제의 억제제로서 5,7-치환된-이미다조［1,2-ｃ］피리미딘
PE20130216A1 (es) 2010-05-21 2013-02-27 Incyte Corp Formulacion topica para un inhibidor de jak
US9034884B2 (en) 2010-11-19 2015-05-19 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
PE20140146A1 (es) 2010-11-19 2014-02-06 Incyte Corp Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak
WO2012076063A1 (fr) 2010-12-10 2012-06-14 Rottapharm S.P.A. Dérivés de pyridinamide en tant qu'antagonistes de récepteur ep4
WO2012116248A1 (fr) 2011-02-24 2012-08-30 Massachusetts Institute Of Technology Isoformes d'arnm à épissage alternatif en tant qu'indicateurs de pronostic de cancer métastatique
CN103797010B (zh) 2011-06-20 2016-02-24 因塞特控股公司 作为jak抑制剂的氮杂环丁烷基苯基、吡啶基或吡嗪基甲酰胺衍生物
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
CA2849168A1 (fr) 2011-09-22 2013-03-28 Merck Sharp & Dohme Corp. Cycloalkylnitrile pyrazole carboxamides en tant qu'inhibiteurs de janus kinase
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
TWI646099B (zh) 2012-11-01 2019-01-01 英塞特控股公司 作爲ｊａｋ抑制劑之三環稠合噻吩衍生物
PH12020551186B1 (en) 2012-11-15 2024-03-20 Incyte Holdings Corp Sustained-release dosage forms of ruxolitinib
RS62867B1 (sr) 2013-03-06 2022-02-28 Incyte Holdings Corp Postupci i intermedijeri za dobijanje inhibitora jak
EP2803668A1 (fr) 2013-05-17 2014-11-19 Boehringer Ingelheim International Gmbh Nouveau (cyano-dimethyl-methyl)-isoxazoles et - [1,3,4] thiadiazoles
BR112015028873A2 (pt) 2013-05-17 2017-07-25 Hoffmann La Roche heteroaril-diidro-pirimidinas interligados na posição 6, para o tratamento e profilaxia de infecção pelo vírus da hepatite b
HUE033587T2 (hu) 2013-05-17 2017-12-28 Incyte Corp Bipirazol-származékok mint JAK inhibitorok
TWI733288B (zh) 2013-05-17 2021-07-11 愛爾蘭商健生科學愛爾蘭無限公司 胺磺醯基吡咯醯胺衍生物及其作為用於治療ｂ型肝炎藥物的用途
US9371282B2 (en) 2013-05-17 2016-06-21 Centrexion Therapeutics Corporation Somatostatin receptor subtype 4 (SSTR4) agonists
SMT202000315T1 (it) 2013-08-07 2020-07-08 Incyte Corp Forme di dosaggio a rilascio prolungato per un inibitore di jak1
KR20160136323A (ko) 2014-02-28 2016-11-29 인사이트 코포레이션 골수형성이상증후군 치료용 jak1 억제제
MA39987A (fr) 2014-04-30 2017-03-08 Incyte Corp Procédés de préparation d'un inhibiteur de jak1 et nouvelles formes associées
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
WO2015191677A1 (fr) * 2014-06-11 2015-12-17 Incyte Corporation Dérivés d'hétéroarylaminoalkylphényle bicycliques à titre d'inhibiteurs de pi3k
DK3233843T3 (da) 2014-12-16 2019-11-18 Novartis Ag Isoxazol-hydraxamsyreforbindelser som LPXC-hæmmere
CN109867676B (zh) * 2017-12-01 2020-10-30 北京普祺医药科技有限公司 一种吡咯并嘧啶衍生的化合物、药物组合物以及其用途

Also Published As

Publication number Publication date
US11685731B2 (en) 2023-06-27
AR122505A1 (es) 2022-09-14
PL4157831T3 (pl) 2025-03-03
HRP20241560T1 (hr) 2025-01-17
HUE069125T2 (hu) 2025-02-28
CL2024002552A1 (es) 2025-01-17
JP2023528868A (ja) 2023-07-06
CN115836065B (zh) 2025-07-01
IL298118B2 (en) 2026-02-01
MX2022015221A (es) 2023-03-08
WO2021247668A1 (fr) 2021-12-09
CA3184275A1 (fr) 2021-12-09
IL298118B1 (en) 2025-10-01
EP4157831A1 (fr) 2023-04-05
SMT202400509T1 (it) 2025-01-14
US20210380563A1 (en) 2021-12-09
FI4157831T3 (fi) 2024-12-02
AU2021283271A1 (en) 2022-12-15
PH12022553277A1 (en) 2024-02-19
RS66432B1 (sr) 2025-02-28
IL298118A (en) 2023-01-01
CR20220612A (es) 2023-04-11
ECSP22091930A (es) 2023-02-28
PE20231102A1 (es) 2023-07-19
CL2022003363A1 (es) 2023-05-19
SI4157831T1 (sl) 2025-02-28
MD4157831T2 (ro) 2025-04-30
TWI897972B (zh) 2025-09-21
BR112022024632A2 (pt) 2023-02-28
KR20230027086A (ko) 2023-02-27
CL2024002551A1 (es) 2025-01-10
CO2022017344A2 (es) 2023-03-07
DK4157831T3 (da) 2024-11-25
EP4157831B1 (fr) 2024-10-30
LT4157831T (lt) 2024-12-27
ES2998487T3 (en) 2025-02-20
JP7802696B2 (ja) 2026-01-20
CN115836065A (zh) 2023-03-21
PT4157831T (pt) 2024-12-20
TW202210471A (zh) 2022-03-16

Similar Documents

Publication Publication Date Title
MA59824B1 (fr) Procédés de préparation d'un inhibiteur de jak1
Oi et al. Stereospecific conversion of chiral 1, 2-cyclic sulfates to chiral imidazolines
MA49956B1 (fr) Composés de pyrimidine utilisés en tant qu'inhibiteurs de kinase jak
EA200400027A1 (ru) Замещенные сульфонамиды, способ их получения и их применение в качестве лечебного средства для лечения расстройств цнс, ожирения и диабета типа ii
RU2002130710A (ru) Производное пиридин-1-оксида и способ его преобразования в фармацевтически эффективные соединения
HU192105B (en) Process for preparing alkane-cerboxylic acid derivatives and pharmaceutical compositions containing them
PL163178B1 (pl) Sposób wytwarzania nowych pochodnych kwasu 1,3-dioksanoalkenowego PL PL PL
EA200401519A1 (ru) N- ациламинобензольные производные в качестве селективных ингибиторов моноаминооксидазы b
US4594425A (en) Heterocyclic compounds as antiallergic agents
KR950702537A (ko) 키랄[[(2-브로모에틸)아미노]메틸]-2-니트로-1H-이미디졸-1-에탄올 및 관련화합물의 신규 제조 방법(Novel Process for preparing Chiral [[(2-Bromoethyl)aminomethyl]-2-nitro-1H-imidazol-1-ethanol and Related Compounds)
IL159814A0 (en) Process for the production of beraprost an its salts
HU200755B (en) Process for producing optically active alcohol derivatives by using asymmetrically modified compounds of boron hydride type
NO20020523L (no) Nye 2-dekarboksy-2-fosfinikoprostaglandin F-analoger
MA29852B1 (fr) Synthese d'inhibiteurs de la renine impliquant une reaction de cycloaddition
EA199901021A1 (ru) Способ получения сертиндола
US4581457A (en) Heterocyclic sulfonamides
MA24670A1 (fr) Methode pour la preparation d'acides 4-phenyl-4-cyano-cyclohexanoiques substitues
EP0092328B1 (fr) Dérivés d'imidazoline
UA46741C2 (uk) Спосіб одержання діізопінокамфеїлхлорборану у реакційному середовищі, спосіб відновлення прохірального кетону
FR2450246A1 (fr) Procede de separation des isomeres optiques du 1-(o-methoxy-phenoxy)-3-isopropyl-amino-propane-2-ol et compositions pharmaceutiques contenant l'antipode levogyre, utile notamment comme agent b-bloquant
EP0947499A2 (fr) Procédé de préparation de la sertraline racémique
US4562199A (en) Imidazole derivatives, compositions and use
MXPA03011647A (es) Procedimiento de resolucion para el acido ( r ) - (-) - 2-hidroxi - 2- (2 - clorofenil) acetico.
CA1212115A (fr) Derives d'imidazole et sels connexes, leur synthese et leur emploi en pharmacie
JPS62114979A (ja) オレフインのエポキシ化法